Cascade Chemistry starts $14 million API manufacturing expansion

Cascade's planned new facility in Eugene

CDMO says increased customer demand for clinical API supply has outstripped its cGMP manufacturing capacity

The new facilities, expected to be operational in the first quarter of 2022, will almost triple the company’s floor space and will include 2,200 square feet of new analytical labs, a robust quality system and additional office space.

The 28,000-square-foot building currently under construction will initially include five suites for Phase 1 and Phase 2 cGMP manufacturing with flow hydrogenation and reactors up to 400 liters.

Additional capacity for API Phase 3 and commercial scale cGMP manufacturing up to 1,000 liters will be added in 2022.

The second building, with 7,000 square feet, is reserved for future expansion.

Cascade President, Jeremiah Marsden said increased customer demand for clinical API supply had outstripped the company’s cGMP manufacturing capacity.

“We ultimately will expand into the second new building to build further cGMP capacity for commercial-stage low-volume, high-value pharmaceuticals,” he added.

Cascade will host a new facility groundbreaking on February 19 at 12pm PT at its Cascade Woodruff Site in Eugene.